$Bob's and Jbem's Bitchin' Bios

[BioSpecialist]

(LPCN)ADCOM on January 10 = 200% possible / Low Valuation of $74 million and only 21.2 million shares outstanding makes this stock attractive .

HIGH RISK Bio Stock but with significant upside potential if everything goes well . ADCOM meeting on January 10 for Lipocine´s Tlando the potential FIRST Oral product for the treatment of hypogonadism , if outcome is positive the stock will likely jump close or above $10 easily especially because of its low float more infos below and good luck

Lipocine (LPCN)

Market Cap: $74 Million
Cash: $25.7 Million
Price: $3.50

Shares Out: 21.2 Million


Latest Presentation
http://files.shareholder.com/downloads/AMDA-2BVSIV/5783990236x0x958103/2EB5BE41-D62A-4270-9634-2DAE6A0E1438/LPCN_11.08.17_long_FINAL__002_.pdf


The previously scheduled Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) meeting on January 10, 2018 to discuss the NDA for TLANDO remains unchanged.

The FDA has assigned a new Prescription Drug User Fee Act (“PDUFA”) goal date of May 8, 2018.

TLANDO™: Potential first oral TRT option

-Differentiated product targeting ~$2.0 billion established US TRT market
-Poised to meet and exceed unmet need